Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo Rispens

Showing results (91-100 of 304) with videos related to

Pageof 31
Sort By:
Annals of the Rheumatic Diseases|August 14, 2014
Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-upErik H Vogelzang, Eva L Kneepkens, Michael T Nurmohamed, et al.
European Journal of Immunology|March 12, 2026
Transcriptome-Proteome Analysis of Human Naive and Memory B Cell Subsets Reveals Isotype and Subclass-Specific PhenotypesJana Koers, Arie J Hoogendijk, Simon Tol, et al.
Journal of Immunological Methods|August 10, 2011
Differential effect of drug interference in immunogenicity assaysMargreet H Hart, Henk de Vrieze, Diana Wouters, et al.
Scientific Reports|November 23, 2016
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycansGillian Dekkers, Rosina Plomp, Carolien A M Koeleman, et al.
Rheumatology (Oxford, England)|December 25, 2012
Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patternsLotte A van de Stadt, Pauline A van Schouwenburg, Suzanne Bryde, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 22, 2017
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patientsCyra E Leurs, Zoé LE van Kempen, Iris Dekker, et al.
Frontiers in Immunology|November 9, 2018
IgG Glyco-Engineering to Improve IVIg PotencyChristine W Bruggeman, Gillian Dekkers, Remco Visser, et al.
Frontiers in Immunology|February 13, 2023
Factors affecting IgG4-mediated complement activationNienke Oskam, Timon Damelang, Marij Streutker, et al.
Rheumatology (Oxford, England)|November 7, 2019
The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patientsLea C Berkhout, Merel J l'Ami, Charlotte L M Krieckaert, et al.
Scientific Reports|January 8, 2022
Human IgE does not bind to human FcRnMaximilian Brinkhaus, Elvera J van der Kooi, Arthur E H Bentlage, et al.
Pageof 31

Showing results (91-100 of 304) with videos related to

Sort By:
Pageof 31
Annals of the Rheumatic Diseases|August 14, 2014
Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-upErik H Vogelzang, Eva L Kneepkens, Michael T Nurmohamed, et al.
European Journal of Immunology|March 12, 2026
Transcriptome-Proteome Analysis of Human Naive and Memory B Cell Subsets Reveals Isotype and Subclass-Specific PhenotypesJana Koers, Arie J Hoogendijk, Simon Tol, et al.
Journal of Immunological Methods|August 10, 2011
Differential effect of drug interference in immunogenicity assaysMargreet H Hart, Henk de Vrieze, Diana Wouters, et al.
Scientific Reports|November 23, 2016
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycansGillian Dekkers, Rosina Plomp, Carolien A M Koeleman, et al.
Rheumatology (Oxford, England)|December 25, 2012
Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patternsLotte A van de Stadt, Pauline A van Schouwenburg, Suzanne Bryde, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 22, 2017
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patientsCyra E Leurs, Zoé LE van Kempen, Iris Dekker, et al.
Frontiers in Immunology|November 9, 2018
IgG Glyco-Engineering to Improve IVIg PotencyChristine W Bruggeman, Gillian Dekkers, Remco Visser, et al.
Frontiers in Immunology|February 13, 2023
Factors affecting IgG4-mediated complement activationNienke Oskam, Timon Damelang, Marij Streutker, et al.
Rheumatology (Oxford, England)|November 7, 2019
The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patientsLea C Berkhout, Merel J l'Ami, Charlotte L M Krieckaert, et al.
Scientific Reports|January 8, 2022
Human IgE does not bind to human FcRnMaximilian Brinkhaus, Elvera J van der Kooi, Arthur E H Bentlage, et al.
Pageof 31